We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A different angler

3 June 2013 By Robert Cyran

The U.S. pharma giant paid $1.3 bln for Esperion in 2004, but shut it down when a promising drug didn’t work out. Now the firm is going public anew. Same name, founder and a cholesterol treatment it discovered – and with Pfizer as a backer. It’s a novel form of schmuck insurance.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)